Medtronic PLC (NYSE:MDT) – Research analysts at Leerink Swann issued their Q1 2019 EPS estimates for Medtronic in a research note issued on Wednesday. Leerink Swann analyst D. Antalffy anticipates that the medical technology company will post earnings per share of $1.24 for the quarter. Leerink Swann currently has a “Market Perform” rating and a $85.00 price objective on the stock. Leerink Swann also issued estimates for Medtronic’s Q2 2019 earnings at $1.21 EPS, Q3 2019 earnings at $1.27 EPS and Q4 2019 earnings at $1.43 EPS.

A number of other equities research analysts have also recently issued reports on the company. Zacks Investment Research cut Medtronic from a “hold” rating to a “sell” rating in a research note on Tuesday, September 12th. Wells Fargo & Company cut Medtronic from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $93.00 to $83.00 in a research note on Monday, October 9th. Stifel Nicolaus lowered their price objective on Medtronic from $91.00 to $83.00 and set a “hold” rating on the stock in a research note on Monday, October 9th. SunTrust Banks restated a “buy” rating and issued a $96.00 price objective on shares of Medtronic in a research note on Friday, November 3rd. Finally, Cowen restated a “buy” rating and issued a $95.00 price objective on shares of Medtronic in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have issued a buy rating to the stock. Medtronic presently has a consensus rating of “Hold” and an average price target of $88.02.

Shares of Medtronic (NYSE MDT) traded down $0.86 during trading on Monday, reaching $81.27. The company had a trading volume of 5,993,000 shares, compared to its average volume of 4,941,329. Medtronic has a fifty-two week low of $69.35 and a fifty-two week high of $89.72. The company has a market cap of $110,006.42, a PE ratio of 17.51, a P/E/G ratio of 2.24 and a beta of 1.00. The company has a quick ratio of 2.05, a current ratio of 2.40 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.08. The company had revenue of $7.05 billion for the quarter, compared to the consensus estimate of $7.05 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.12 EPS.

In other news, EVP Bryan C. Hanson sold 16,000 shares of the company’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $78.03, for a total transaction of $1,248,480.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Omar Ishrak sold 140,407 shares of the company’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $81.63, for a total value of $11,461,423.41. Following the sale, the chief executive officer now owns 668,503 shares in the company, valued at $54,569,899.89. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 172,407 shares of company stock worth $13,974,223. Company insiders own 0.31% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in MDT. AXA increased its position in shares of Medtronic by 4.3% in the third quarter. AXA now owns 702,275 shares of the medical technology company’s stock worth $54,616,000 after purchasing an additional 28,709 shares during the last quarter. Crestwood Advisors Group LLC increased its position in shares of Medtronic by 1.7% in the third quarter. Crestwood Advisors Group LLC now owns 251,995 shares of the medical technology company’s stock worth $19,598,000 after purchasing an additional 4,275 shares during the last quarter. GSA Capital Partners LLP increased its position in shares of Medtronic by 468.3% in the third quarter. GSA Capital Partners LLP now owns 41,130 shares of the medical technology company’s stock worth $3,199,000 after purchasing an additional 33,893 shares during the last quarter. Gofen & Glossberg LLC IL increased its position in shares of Medtronic by 9.2% in the third quarter. Gofen & Glossberg LLC IL now owns 7,599 shares of the medical technology company’s stock worth $591,000 after purchasing an additional 642 shares during the last quarter. Finally, Moors & Cabot Inc. increased its position in shares of Medtronic by 10.2% in the third quarter. Moors & Cabot Inc. now owns 47,640 shares of the medical technology company’s stock worth $3,721,000 after purchasing an additional 4,413 shares during the last quarter. Hedge funds and other institutional investors own 81.85% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Weighs in on Medtronic PLC’s Q1 2019 Earnings (MDT)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/12/04/leerink-swann-weighs-in-on-medtronic-plcs-q1-2019-earnings-mdt.html.

About Medtronic

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Earnings History and Estimates for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.